DeGen Medical Seeks Dismissal of Carlsmed Patent Suit
News related to:DeGen Medical, Inc · 1 min read
Florence, SC, Nov. 15, 2026 /CourierPR/ -- DeGen Medical, Inc., a company specializing in patient-specific spinal implants, has taken a significant step in its ongoing legal battle with Carlsmed, Inc. The legal action, initiated by Carlsmed on September 15, 2026, involves eight patents against DeGen's innovative spinal implant technology. DeGen has now filed a motion in the U.S. District Court for the District of South Carolina, seeking to dismiss key portions of the patent infringement complaint.
According to the motion, DeGen argues that four of the asserted patents should be dismissed because they claim abstract information processing, which is not eligible for patent protection under Section 101 of the Patent Act. The company also seeks to dismiss Carlsmed's allegations of willfulness and demand for enhanced damages. Additionally, DeGen contests two further infringement theories that the complaint does not plausibly support.
Craig Black, CEO of DeGen Medical, emphasized the company's commitment to its human-centered approach to patient-specific implants.
DeGen Medical is represented by Turner, Padget, Graham & Laney, P.A. (Florence, S.C.) and MacMillan, Sobanski & Todd, LLC (Toledo, Ohio). The company remains committed to defending this case through to its conclusion and continues to serve surgeons and patients without interruption.
The legal dispute highlights the ongoing challenges in the medical technology industry, particularly regarding the patentability of computer-implemented methods. As the case progresses, it will be crucial to observe how the court rules on the specific claims and the broader implications for the patentability of such technologies in the medical field.